Uro Pipeline

Uro Pipeline: Supplemental application submitted for advanced RCC treatmentOther pipeline developments include an agent to control pain in IC/BPS patients, an antibody to treat prostate and bladder cancer, an injectable OAB treatment, and more.
Uro Pipeline: Phase IIb study begins for intraprostatic localized PCa drugOther pipeline developments include a new company formed to develop OAB treatments, a phase III urothelial cancer study meeting its primary endpoint, the formation of a partnership to study RCC treatment, and more.
Uro Pipeline: FDA accepts two supplemental applications for mUC agentOther pipeline developments include efficacy results for a bladder and prostate cancer drug, an infertility tool to predict sperm quality, the initiation of an immunotherapy combination for mUC, and more.
Uro Pipeline: FDA accepts biologics license application for bladder Ca agentOther pipeline developments discussed include an implantable device for OAB treatment, a subcutaneous hypogonadism treatment, efficacy results for an HPV drug, and the status of a device-based BPH treatment.
Uro Pipeline: Data from mUC combination therapy suggests efficacy, safetyOther pipeline developments discussed include a bladder cancer test, a male infertility assay, and the first oral dosage treatment for hypogonadism.
Uro Pipeline: FDA committee votes in favor of nocturia treatment approvalOther pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.
Uro Pipeline: Bladder Ca drug-device combination begins second phase Ib trialA bladder cancer drug-device combination, a localized prostate cancer agent, and a new surgical robot are among other treatments in the pipeline discussed in this round-up.
Uro Pipeline: Trial launched for drugs' use in metastatic, hormone-sensitive PCaA novel oral TRT agent, bladder control system, and localized prostate cancer agent are among other treatments in the pipeline discussed in this round-up.
Uro Pipeline: FDA grants priority review to advanced bladder Ca agentAlso look for coverage of products in the pipeline for bladder pain syndrome/interstitial cystitis, prostate cancer, and male infertility.
Uro Pipeline: Phase III data show drug’s benefit in castrate-resistant PCaOther pipeline products discussed in this article include agents for urinary catheter blockage, prostate cancer, bladder cancer, and overactive bladder.